Ortho-mcneil Pharmaceutical Corp.

Janssen Pharmaceutica Nv

Martek Biosciences Corporation

Other

Dsm IP Assets B.v.

Jung S Lee

John R Carson

William Robert Barclay

Mark Andrew Youngman

James H Flatt

Michele C Jetter

Linda Mary Arterburn

Bindi Dangi

Philip J Rybczynski

Keith T Demarest

Jay M Matthews

Neil Francis Leininger

Krishna Raman

Xiaoli Chen

Dutt V Vinjamoori

Chris Connor Luigart

Mary Van Elswyk

Chris Luigart

The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-containing composition that has not been conventionally processed. The reacted composition can be further processed by distillation.

Production and purification of esters of polyunsaturated fatty acids

Disclosed are novel oxylipins that are derived from &#x3b3;-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.

Oxylipins from stearidonic acid and &#x3b3;-linolenic acid and methods of making and using the same

Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.

Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

This invention is directed to 3-(diheteroarylmethylene)-8-azabicyclo[3.2.1] octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1] octane derivatives useful as &#x3b4;-opioid, &#x3bc;-opioid, or &#x3b4;-opioid and &#x3bc;-opioid receptor receptor modulators. Depending on their agonist or antagonist effect, the compounds are useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.

3-(diheteroarylmethylene)-8-azabicyclo[3.2.1]octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators

The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes.

Methods of using substituted tetralins and indanes

The present invention provides compounds of the formula:wherein m is 0, 1 or 2; p is 0 or 1; Y is O, S, S(O) or S(O)and Rto Rare various substituents as selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function.

Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application

Growing community of inventors

Ambler, PA, United States of America

Jung S Lee